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NADPH oxidase 5 (NOX5) is a homologue of the gp91phox subunit of the phagocyte 
NADPH oxidase, which generates reactive oxygen species (ROS). NOX5 is involved 
in sperm motility and vascular contraction and has been implicated in diabetic 
nephropathy, atherosclerosis and stroke. The function of NOX5 in the heart is unknown. 
Since NOX5 is a Ca2+-sensitive, pro-contractile NOX isoform, we questioned whether 
it plays a role in cardiac pathophysiology. Studies were performed in i) cardiac tissue 
from patients undergoing heart transplant for cardiomyopathy and heart failure, ii) 
NOX5-expressing rat cardiomyocytes, and iii) mice expressing human NOX5 in a 
cardiomyocyte-specific manner. Cardiac hypertrophy was induced in mice by 
transverse aorta coarctation (TAC) and Ang II infusion. NOX5 expression was 
increased in human failing hearts. Rat cardiomyocytes infected with AdNOX5 
exhibited elevated ROS levels with significant hypertrophy and associated increased 
expression of ANP and β-MHC and pro-hypertrophic genes (Nppa, Nppb, Myh7). 
These effects were amplified by Ang II and reduced by NAC and diltiazem. Pressure 
overload and Ang II infusion induced left ventricular hypertrophy, interstitial fibrosis, 
and contractile dysfunction, responses that were exaggerated in cardiac-specific NOX5 
knock in mice. These phenomena were associated with increased ROS levels and 
activation of redox-sensitive MAP kinases. NAC treatment reduced cardiac oxidative 
stress and attenuated cardiac hypertrophy in NOX5 mice. Our study defines Ca2+-
regulated NOX5 as an important NOX isoform involved in oxidative stress- and 
MAPK- mediated cardiac hypertrophy and contractile dysfunction.  














Heart failure, which is among the most common causes of mortality, is increasing in 
prevalence worldwide1. A major risk factor for heart failure is cardiac hypertrophy. 
Cardiac hypertrophy is initially a compensatory mechanism in response to various 
mechanical and neurohormonal stimuli, such as hypertension, chronic pressure 
overload, valvular heart disease, ischemic events and endocrine disorders2,3. However, 
sustained or excessive cardiac hypertrophy can progress to decompensation, ventricular 
contractile dysfunction, heart failure and subsequent death2,3. While there has been 
some development in new drugs for heart failure4, effective treatments for preventing 
or reversing the progression of cardiac hypertrophy still remain inadequate. This relates 
in large part to the lack of understanding of underlying molecular mechanisms5.  
Although there are many causes of cardiac hypertrophy and heart failure, most share 
a critical common pathological mechanism: oxidative stress6. Oxidative stress is an 
imbalance between the production and clearance of reactive oxygen species (ROS)7. In 
patients with heart failure, production of ROS is increased in the myocardium and 
plasma, and is associated with cardiac dysfunction8. Reactive oxygen species contribute 
to cardiac remodeling, apoptosis, necrosis, and myocardial dysfunction8,9. Enzymatic 
sources for ROS, such as the mitochondria, cytochrome P450, xanthine oxidases, 
uncoupled nitric oxide synthases, and NADPH oxidases (NOXs) are all considered 
relevant sources of ROS in cardiac hypertrophy10. Among these sources, only NOXs 
are considered to produce ROS specifically (professional oxidases), and increasing 
evidence indicates that NOXs are critical determinants of myocardial ROS generation11. 
Seven NOX isoforms have been identified, including NOX1~5 and dual domain 
oxidases (DUOX) 1~212. All NOXs possess six transmembrane domains with two 
haem-binding regions and a NADPH-binding region on the intracellular C-terminus, 
which catalyze the reduction of O2 to produce superoxide (O2
-), which leads to 
generation of secondary ROS, including hydrogen peroxide (H2O2), hydroxyl radical, 
peroxynitrite, and hypochlorous acid13,14. Of the seven known Nox isoforms, Nox2 and 
Nox4 are the predominant proteins expressed in the heart, at least in rodent models 15,16. 
Nox2 is involved in the development of cardiac hypertrophy and remodeling through 
increasing generation of ROS17. However, the role of Nox4 in cardiac hypertrophy is 
controversial. Nox4 has ben shown to promote cardiac hypertrophy by activation of 
redox signaling pathways in response to hypertrophic stimuli18. On the other hand, 
Nox4 was also found to have protective effects against chronic pressure overload-
induced remodeling in mice19-20. These cardioprotective effects of Nox4 involve 
multiple mechanisms including paracrine effects on myocardial capillary density and 
activation of the cytoprotective transcription factor Nuclear factor erythroid-derived 2-
like 2 (Nrf2)19-20. 
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Among the NOX family, NOX5 appears to be especially important in human 
cardiovascular cells21. Unlike other NOXs, NOX5 gene is absent in rodents, it does not 
require NADPH oxidase subunits for its activation and it is highly sensitive to changes 
in intracellular Ca2+ concentration22. Persistent hypertrophic stimuli are potent inducers 
of sustained increased intracellular Ca2+ concentration23. Accordingly, it is 
reasonable to assume that NOX5-induced ROS generation may be especially important 
in the development of cardiac hypertrophy. However, there is a paucity of information 
about the role of NOX5 in the heart and its putative mechanistic role in cardiac 
hypertrophy and heart failure are unknown. To address this, we generated mice that 
express human NOX5 in a cardiomyocyte-specific manner and induced cardiac 
hypertrophy using the transverse aorta coarctation (TAC) and Ang Ⅱ infusion approach. 
Molecular mechanisms were interrogated in mice cardiac tissue and rat cardiomyocytes 
expressing human NOX5.  
 
Materials and methods 
A detailed description about the materials and methods that were used in this study is 
available in the online-only Data Supplement, including Reagents, Human heart 
samples, Cardiac-Specific NOX5-Knockin Mice, Animal models24, 
Echocardiography25, Histological analysis26, Cultured neonatal rat cardiac myocytes 
and Recombinant Adenoviral Vectors27, Immunofluorescent staining28, Quantitative 
Real-time PCR, Western blotting29, Dihydroethidium (DHE) staining30, measurement 
of NADPH oxidase activity and superoxide anion (O2
-) production31, measurement of 
H2O2 levels, measurement of intracellular calcium in cardiomyocytes and Statistical 
analysis. All data were expressed as means ± SEM. Two-tailed student’s t-test was used 
to compare the means of two-group samples. One-way ANOVA with Bonferroni 
(assuming equal variances) or Tamhane’s T2 (equal variances not assumed) tests was 
used to compare the means of multiple groups. All statistical analyses were performed 
using SPSS 19.0 (Statistical Package for the Social Sciences) software. A value of 
P<0.05 was considered significant.  
 
Results 
NOX5 expression is increased in failing human hearts.  
In order to explore the NAPDH oxidase subunits status in the development of 
pathological cardiac hypertrophy, we first performed quantitative polymerase chain 
reaction (qPCR) and western blot analyses to investigate expression levels of NADPH 
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oxidase subunits in mice heart samples. Our qPCR and western blot results indicated 
that Nox4 levels were significantly increased in response to pressure overload. (Figure 
S1B and S1C). In order to better understand the status of Noxs in the clinical situation, 
we also checked expression of Nox isoforms in failing human hearts. Our results 
showed that expression levels of both NOX5 and NOX4 in failing human hearts were 
increased compared with normal donor hearts, moreover, the expression of NOX5 gene 
is higher both in mRNA and protein levels than that of NOX4 (Figure 1A and 1B). 
Other Nox isoforms, NOX1 and NOX2 and NADPH oxidase subunits p22phox, p40phox, 
p47phox, and p7phox did not differ significantly between the two groups (Figure 1A and 
1B). Given that there are 6 isoforms of NOX5, i.e., NOX5(V1)-NOX5(V6). In order to 
clarify which splicing isoform of NOX5 is up-regulated in human failing hearts, we 
examined the mRNA expression of all 6 NOX5 isoforms in human failing hearts. Our 
data demonstrate that mRNA expression of V1 and V2 was increased compared with 
normal donor hearts. V2 was especially abundant (Figure 1C). Thus, the NOX5 V2 was 
applied in our study. 
Immunohistochemistry staining also showed that failing hearts expressed higher 
NOX5 protein levels than nonfailing hearts (Figure S1D). Moreover, high 
magnification images showed that NOX5 was present in some endothelial cells of 
intramyocardial blood vessels and expressed primarily in cardiomyocytes. Furthermore, 
the increased NOX5 is predominantly localized in the cytoplasm and to a lesser extent 
in the plasma membrane. Additionally, we performed immunofluorescence staining to 
clarify the cellular expression patterns of NOX5 in human heart tissue. As shown in 
Figure 1E, NOX5 was specifically and significantly increased in cardiomyocytes versus 
other cell types in failing hearts compared with the nonfailing hearts. 
NOX5 exacerbates Ang II-induced cardiomyocyte hypertrophy in vitro.  
Cardiomyocyte enlargement is the most defining characteristic of cardiac 
hypertrophy. To evaluate the impact of NOX5 on cardiac hypertrophy, a gain of 
function assay was performed by infecting cultured NRVMs with adenoviral vector 
encoding human NOX5 cDNA (AdNOX5). The efficiency of lentivirus-mediated gene 
expression was validated by Western blotting in NRVMs (Figure 2A). Isolated NRVMs 
were infected with adenoviruses expressing either NOX5 (AdNOX5) or the empty 
vector (AdVector) as a control, then, these cells were treated with either Ang II or PBS 
as a control for 48 h before immunostaining for α-actinin to determine cardiomyocyte 
surface area. Under basal conditions (PBS administration), there was no significant 
difference in cardiomyocyte surface area between groups. Compared with AdVector-
infected controls, AdNOX5 infection-mediated NOX5 expression significantly 
increased AngII-induced cardiomyocyte hypertrophy, as evidenced by the increase in 
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cardiomyocyte surface area and mRNA and protein levels of hypertrophy markers (ANP, 
BNP and β-MHC) (Figure 2B-2D). To confirm the pro-hypertrophy action of NOX5 in 
human cardiomyocytes, we also explored effects of NOX5 on cardiomyocyte 
hypertrophy using human AC16 cardiomyocytes. Consistent with the results in rat 
cardiomyocytes, under basal conditions (PBS administration), there was no significant 
difference in cardiomyocyte surface area between groups. However, compared with 
AdVector-infected controls, AdNOX5 infection-mediated NOX5 expression 
significantly increased AngII-induced cardiomyocyte hypertrophy, as evidenced by the 
increase in cardiomyocyte surface area and levels of hypertrophy markers (ANP and β-
MHC), (Figure 2E-2G). 
Together, these results indicate that NOX5 promotes cardiomyocyte hypertrophy 
in vitro. Mechanical stress and hormonal stimuli are common triggers in cardiac 
hypertrophy. Stimulating myocytes with Ang II or mechanical stretch directly reflects 
how myocytes respond to hypertrophic stimuli at the cellular level. However, the 
pathophysiology of hypertrophy is complex and multifactorial, as it influences several 
cellular and molecular systems. Since in vitro conditions do not fully represent the 
features observed in vivo, and to gain insights on the pathophysiological role of NOX5 
in the whole organism, we generated cardiomyocyte specific NOX5 transgenic mice 
and focus mainly on the in vivo experiments. 
TAC and Ang II -induced cardiac hypertrophy are exaggerated in NOX5-
expressing mice. 
To determine whether cardiac NOX5 influences cardiac status in vivo we generated 
cardiac-specific NOX5 transgenic (NOX5-Tg) mice that express human NOX5 using 
the a-myosin heavy chain promoter (Figure 3A). Two independent lines of NOX5-Tg 
mice (Tg1 and Tg2) were successfully established and western blotting results showed 
that the Tg2 line had the highest level of NOX5 expression in the heart, thus, the Tg2 
was selected for the following experiments (Figure 3B and 3C). Our western blotting 
results showed Nox5 transgene does not influence endogenous Noxs (NOX1, NOX2, 
NOX4) expression (Figure S2A). 
NOX5-Tg and the wild type (WT) control mice were challenged with TAC surgery 
or sham operation for 4 weeks. Under basal conditions (Sham), the NOX5-Tg mice did 
not show any alterations in cardiac structure or function compared with the WT control 
group (Figure 3D and 3E). However, compared to the TAC-treated WT mice, the 
myocardial contractile function was significantly reduced in NOX5-Tg mice, as shown 
by echocardiography measurements of left ventricular end-diastolic diameter (LVEDd), 
LV end-systolic diameter (LVESd), LV ejection fraction (LVEF) and LV 
shortening fraction (LVFS) (Figure 3D and 3E). We subsequently sought to explore the 
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effect of NOX5 on cardiac remodeling. After four weeks of TAC, NOX5-Tg mice 
showed an enhanced hypertrophic response compared with the WT group, as indicated 
by increased HW/BW and HW/TL ratios (Figure 3F). In addition, NOX5-Tg mice had 
significantly increased cardiomyocyte size after 4 weeks of TAC, which was identified 
by H&E staining of heart sections and quantified based on the cardiomyocyte cross-
sectional area in NOX5-Tg and control mice (Figure 3G and 3H). These changes were 
accompanied by elevated levels of cardiac fetal and pro-hypertrophic genes in TAC-
treated NOX5-Tg mice (Figure 3I and 3J). Furthermore, picrosirius red (PSR)-stained 
heart sections exhibited more prominent interstitial fibrosis in NOX5-Tg mice 
compared with controls (Figure 3G and 3H). Indices of collagen synthesis, including 
collagen I (COL1A1) and collagen III (COL3A1) were also markedly increased in 
NOX5-Tg hearts compared with controls (Figure 3I and 3J). Together these data 
demonstrate that NOX5 exaggerates pressure overload-induced cardiac remodeling and 
dysfunction.  
We next examined the potential effect of NOX5 on hypertrophy mediated by Ang II 
infusion to exclude the possibility that these effects of NOX5 were specific to pressure 
overload-induced cardiac hypertrophy. As shown in Figure S2, 4 weeks of Ang II 
infusion in wild-type (WT) mice led to significantly increased HW/BW and HW/TL, 
impaired contractile function and enlarged myocytes compared with saline controls. 
Similar to the results that observed with TAC treatment, the structural remodeling and 
functional changes of the heart induced by Ang II infusion were significantly 
exacerbated by NOX5 over expression. These data indicate that NOX5 is an important 
molecular mediator underlying pathological cardiac hypertrophy induced by both 
pressure overload and hormonal stresses. 
NOX5 promotes ROS production in response to hypertrophic stress.   
It is well known that oxidative stress plays a crucial role in cardiac hypertrophy. 
Furthermore, in an NADPH-dependent manner, NOX5 catalyzes the reduction of O2 to 
produce O2
-, which in turn dismutates to generate H2O2. Thus, we questioned whether 
NOX5 upregulation causes increased ROS generation in the presence of hypertrophic 
stimuli. To address this, we assessed ROS levels in the hearts of NOX5-Tg mice and 
cultured NRVMs by DHE staining. Results showed that TAC induced a significant 
increase in ROS levels in the hearts of WT and NOX5-Tg mice, with significantly 
greater responses in NOX5-expressing mice (Figure 4A). Additionally, we performed 
the lucigenin-enhanced chemiluminescence assay to determine the NADPH oxidase 
activity and O2
- production in cardiac tissue. As a stable ROS, H2O2 was also measured. 
As shown in Figures 4B and 4C, NOX5-Tg mice exhibited increased NADPH-induced 
O2
- production and H2O2 levels under the stress condition, which was concomitant with 
 
 8 
development of cardiac hypertrophy. Consistent with the in vivo results, NOX5 
expression also exhibited higher levels of ROS after Ang II treatment in NRVMs 
compared with the control group (Figure 4D-4F). Together these findings suggest that 
NOX5 promotes ROS production in response to hypertrophic stress. Since ROS can 
alter activation of multiple signaling cascades that participate in regulating cardiac 
hypertrophy, we assessed phosphorylation levels of redox-sensitive mitogen-activated 
protein kinases (MAPK): JNK, ERK, and p38 MAPK, which are downstream signaling 
kinases of ROS and master regulators of cell growth. Our results showed that NOX5-
Tg mice exhibited higher phosphorylation levels of JNK, ERK, and p38 MAPK 
compared with WT controls (Figure 4G). Similar effects were also observed in Ang II-
treated NRVMs (Figure 4H). These data indicate that NOX5 could promote 
accumulation of ROS in the presence of hypertrophic stimuli, which induces activation 
of downstream MAPK signaling pathways.  
Inhibition of ROS abrogates the NOX5-related effect on the hypertrophic response. 
Based on the fact that ROS production significantly promotes cardiac hypertrophy 
development, and NOX5 is capable of increasing ROS levels during cardiac 
hypertrophy, we next questioned whether ROS scavenging could prevent the pro-
hypertrophic effect of NOX5. To address this, we performed in vitro experiments by 
treating cultured NRVMs with NAC or saline as control. As shown in Figures S3A-3C, 
compared with the saline group, NAC treatment significantly reduced Ang II-induced 
cardiomyocyte hypertrophy, as evidenced by the increase in cardiomyocyte surface area 
and mRNA and protein levels of hypertrophy markers (ANP and β-MHC). We also 
treated TAC mice with NAC for 4 weeks. As shown in Figure 5A, NAC significantly 
increased the TAC-induced decrease in heart function, as evidenced by their increased 
EF, FS and decreased LVEDd and LVESd (Figure 5E). Furthermore, NAC significantly 
attenuated the increased heart weight induced by pressure overload in both WT and 
NOX5-Tg mice, as evidenced by their decreased HW/BW and HW/TL (Figure 5B). 
Moreover, treatment with NAC abolished the NOX5-induced increase in 
cardiomyocyte enlargement and interstitial fibrosis as identified by HE and PSR 
staining (Figure 5C and 5D). To further verify this, we used another approach to 
modulate ROS by genetic manipulation of NOX. The S236 domain is critical for ROS 
production within NOX532. To address if the pro-hypertrophic effect of NOX5 is 
dependent on ROS generation, we generated a NOX5 enzyme-dead mutant NOX5(M) 
by substituting the amino acid 236 from serine to arginine which had no ROS producing 
capacity. As shown in Figure 5E, the S236R NOX5 mutant were almost completely 
inactive under AngII stimulation. Compared with the NOX5(M)-infected group, the 
NOX5(WT)-infected group exhibited significantly increased Ang II-induced 
cardiomyocyte hypertrophy, as evidenced by the increase in cardiomyocyte surface area 
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and mRNA and protein levels of hypertrophy markers (Nppa, Myh7), (Figure 5F-5H). 
Together, our data suggest that NOX5-mediated pro-hypertrophic effects are mediated 
in large part through increased production of ROS. 
Ca2+ is required for NOX5 activation.  
It is well established that intracellular Ca2+ concentration ([Ca2+]i) increases in 
response to sustained hypertrophic stimuli. Furthermore, NOX5 activation is dependent 
on [Ca2+]i. Thus, we hypothesized that reducing intracellular Ca
2+ concentration will 
affect activity of NOX5 and its effect on cardiac hypertrophy. To address this, cultured 
NRVMs infected with either AdNOX5 or AdVector were treated with the L-type Ca2+ 
channel blocker diltiazem before the cells were stimulated with Ang II or PBS. Our 
results showed that Ang Ⅱ-induced a significant increase in intracellular Ca2+ 
concentration, effects that were amplified by increased NOX5 and abrogated by 
diltiazem treatment, (Figure 6A).  
We also tested whether NOX5-based NAPDH oxidase contributes to ROS 
production in NRVMs. As shown in figure 6B, Ang II induced a significant increase in 
NAPDH oxidase activity, an increase that was further exaggerated by infection with 
NOX5. Moreover, the increased ROS production was abrogated by diltiazem, similar 
to what we observed for [Ca2+]i. To elucidate the functional significance of Nox5, we 
next measured the hypertrophic responses induced by Ang Ⅱ in NRVMs expressing 
NOX5 that pretreatment with diltiazem or PBS. As shown in figure X, effects of NOX5 
on the hypertrophic response, assessed as cardiomyocyte surface area and expression 
of pro-hypertrophic genes, Nppa and Myh7 were virtually abrogated by diltiazem 
(Figure 6C and 6D).    
 
Discussion 
Pathological cardiac hypertrophy is driven by multiple neuroendocrine hormones, 
such as Ang II, and endothelin 1, as well as mechanical forces, such as chronic pressure 
overload. These factors can directly or indirectly increase ROS production and 
myocardial accumulation of metabolic intermediates, which induce cell death, fibrosis, 
and mitochondrial dysfunction3. Thus, understanding sources of cardiac ROS so that 
disease-specific mechanisms can be targeted to prevent oxidative stress in the 
development of cardiac hypertrophy represents an attractive therapeutic strategy. 
However current pharmacological treatment to prevent or regress cardiac hypertrophy 
is sub-optimal with many patients still dying prematurely from heart failure33. In this 
study, we demonstrate that NOX5, activated by intracellular Ca2+, contributes to the 
development of cardiac hypertrophy through ROS production and activation of redox-
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sensitive MAP kinases.  
Previous studies have shown that increased expression and activity of cardiac 
NOX1 and NOX2 participate in the process of pathological cardiac hypertrophy34,35. 
NOX2 aggravates the hypertrophic response in a model of experimental cardiac 
hypertrophy17. On the other hand, NOX4 seems to be cardioprotective36. Reasons for 
the distinct pathophysiological roles of different NOXs may relate to differential 
patterns of activation, subcellular localization, and type of ROS produced37. While 
NOX5 has been implicated in atherosclerosis, diabetic nephropathy, stroke and 
coronary artery disease36-43, there is a paucity of information about NOX5 in the heart 
and pathogenesis of cardiac disease. NOX5 seems to be important in cardiac 
development since human fetuses with ventricular septal defects, the most common 
form of congenital heart disease, have significantly increased methylation of NOX544. 
A clinical study in patients with acute myocardial infarction showed increased NOX5 
expression in intramyocardial arteries and cardiomyocytes in infarcted tissue45. We 
demonstrate here that NOX5 is present in human heart, that it is important in ROS 
production in cardiomyocytes and that it is abundantly expressed in human heart failure.  
Although it is clear that cardiac NOX5 is upregulated in human heart pathology, 
the functional significance during development of disease remains unclear. It has been 
impossible to investigate this in rats and mice because rodents lack NOX5. To address 
this we generated cardiomyocyte-specific NOX5 knockin mice, which provided a 
unique opportunity to study human NOX5 in an intact system. While there are 
limitations in such transgenic approaches, humanized models are used extensively in 
pre-clinical research to study mechanisms and new therapies of human disease46. In our 
NOX5 knockin mice, cardiac hypertrophy and myocardial dysfunction were markedly 
exaggerated in TAC-induced pressure overload and in Ang II-infused mice. These 
findings indicate that NOX5 is a key player in pathological cardiac remodeling and 
dysfunction due to both mechanical and humoral factors.  
NOXs are professional ROS-producing enzymes47-48. Consistent with previous 
studies, we observed that NOX5 promotes cellular ROS production49, which is 
increased in the myocardium upon hypertrophic stress. Although a large body of 
evidence has demonstrated that ROS influence the pathophysiology of cardiac 
hypertrophy through several mechanisms, including alterations in myofilament calcium 
responsiveness and alterations in cellular energetics50-52, the pro-hypertrophic response 
triggered by ROS in cardiomyocytes remains to be fully defined50. Activation of 
MAPKs may be especially relevant because they are highly redox-sensitive and could 
be activated through an increase in intracellular ROS50-51,53. Activated p38MAPK, JNK, 
and ERK phosphorylate numerous contractile, mitogenic and pro-inflammatory 
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intracellular targets as well as transcription factors, and thus play an important  role in 
regulating  cardiac contraction and hypertrophy50-51,53. Therefore, mechanisms by 
which NOX5 aggravates cardiac hypertrophy and contractile dysfunction are likely 
mediated by activation of ROS-mediated downstream MAPK cascades31. ERK1/2 itself 
has been shown to regulate NOX5 activity, in part through a Ca2+-independent 
mechanism54. Accordingly, it may be possible that in the context of cardiac disease with 
increased NOX5 activity, redox-sensitive ERK1/2 is activated, which in turn further 
activates NOX5. This feedforward phenomenon may contribute to exaggerated cardiac 
damage. MAPKs are master regulators of cell growth and cardiomyocyte function and 
while our study identifies ERK1/2 as being especially important in NOX5-mediated 
cardiomyocyte growth and cardiac hypertrophy, we can not exclude the role of other 
redox-sensitive signaling molecules as well. 
With regard to cardiac fibrosis, the mechanism through which ROS accelerates 
cardiac fibrosis progression has been well studied. ROS mediates pathological fibrosis 
by stimulating fibroblast proliferation, collagen deposition and activation of matrix 
metalloproteinases50-52. Moreover, pharmacological inhibition of redox-sensitive 
signaling pathways could have beneficial effects on cardiac function by decreasing 
proliferation of myocardial fibroblasts50. This was supported by our findings that the 
ROS scavenger NAC ameliorated the NOX5-mediated hypertrophic response, 
indicating that NOX5-mediated pro-hypertrophic effects are mainly dependent on ROS 
generation. Thus, inhibition of NOX5 may represent a promising therapeutic strategy 
to reduce cardiac remodeling in heart disease.  
In cell-free systems and other experimental models, it has been clearly established 
that NOX5 can be directly activated by increased intracellular Ca2+ concentration12,55. 
NOX5 has a unique N terminus, which contains 3-4 Ca2+-binding helix-loop-helix 
structure domains (EF hand)22, which behave like a calmodulin-like activator module12. 
In the absence of Ca2+, the calmodulin-like regulatory EF-domain is partially unfolded 
and detached from the rest of the protein54. When intracellular Ca2+ increases, the Ca2+ 
directly binds to the EF hand. This causes the regulatory domain to binds to the catalytic 
domain causing its activation, and this is why NOX5, unlike other NOXs, does not 
require any NADPH oxidase subunits for its activation. While Ca2+ is thus upstream of 
the NOX5-ROS pathway, intracellular Ca2+ is also downstream of ROS because Ca2+ 
channels and exchangers (L-type Ca2+ channels, sarcoplasmic reticulum (SR) ATPase 
(SERCA), Na+/ Ca2+exchanger, ryanodine receptor and transient receptor potential 
melastatin 2 cation channel), are regulated by ROS56-57. These findings suggest that 
Ca2+ and ROS exert a reciprocal regulation loop on each other: increased intracellular 
Ca2+ induces ROS production, meanwhile increased ROS promotes cytoplasmic Ca2+ 
mobilization. This is particularly significant in the heart, where increased intracellular 
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Ca2+ and ROS interact in a bidirectional manner to amplify the hypertrophic signal 
promoting pathological cardiac hypertrophy58. In our study, Ca2+ channel blockade with 
diltiazem abrogated the NOX5-related effect on the hypertrophic response in 
cardiomyocytes. Together our data suggest that NOX5 acts as an important point of 
cross-talk between ROS and Ca2+ linking signaling pathways such as MAPKs that are 
both redox- and Ca2+-sensitive. These systems are critically involved in the regulation 
of cardiac cell growth, inflammation, fibrosis and contraction and when dysregulated 
lead to pathological cardiac remodeling and contractile dysfunction59. Targeting 
inhibition of the activity of NOX5 may inhibit the reciprocal regulation of Ca2+ and 
ROS, and thus play an important role in certain oxidative stress-related cardiac diseases. 
In conclusion, our multidisciplinary approach from clinically-relevant human 
tissue to transgenic mice clearly delineates a mechanistic role for NOX5 in pathological 
cardiac hypertrophy. In particular we identify Ca2+-sensitive NOX5 and redox-
regulated ERK1/2 as important molecular mechanisms contributing to the development 
of LV hypertrophy, contractile dysfunction and myocardial fibrosis in response to 
pressure and humoral hypertrophic stresses. Our novel findings suggest that NOX5 may 
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Novelty and Significance 
What is new? 
1. NOX5 expression is significantly induced in human failing hearts.  
2. NOX5 exacerbates LV hypertrophy, fibrosis and dysfunction in different preclinical 
mouse cardiac disease models. 
3. NOX5 modulates the development of cardiac hypertrophy by promoting ROS 
production in response to hypertrophic stress.   
4. NOX5 is a point of cross-talk between intracellular calcium and ROS production. 
What is relevant? 
In this study, our findings indicate an important role for NOX5 in cardiomyocyte 
dysfunction in cardiac hypertrophy. Molecular mechanisms underlying NOX5 actions 
involve ROS and MAPK. Our study defines Ca2+-regulated NOX5 as a novel NOX 
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isoform involved in oxidative stress-mediated cardiac hypertrophy and contractile 
dysfunction. Modulating NOX5 may have therapeutic potential by targeting the source 
of ROS. 
Summary 
Our studies in human hearts and NOX5-expressing rodent models identify Ca2+-
regulated NOX5-mediated ROS generation as an important pathway contributing to the 
development of LV hypertrophy, contractile dysfunction and myocardial fibrosis in 
response to hypertrophic stimuli. Our novel findings suggest that NOX5 might be an 




Figure 1. NOX5 expression is increased in failing hearts. 
A, Quantitative polymerase chain reaction (qPCR) analyses of the mRNA levels of 
NOX1, NOX2, NOX4, NOX5, and NOX subunits (p22phox, p40phox, p47phox, p67phox) in 
human heart samples from normal control donors and patients with heart failure, (n=6). 
B, Western blot analysis and quantitative results of NOX1, NOX2, NOX4, NOX5, ANP, 
and β-MHC levels in human heart samples from normal donors and patients with heart 
failure, (n=6). C, mRNA levels of NOX5 splice variants in human heart samples, (n=6). 
D, Expression and cellular localization of NOX5 on human heart sections of normal 
control donors or patients with heart failure using immunohistochemistry staining, (EC: 
endothelial cell; CM: cardiomyocyte; CP: cytoplasm; PM: plasma membrane), (n=6). 
Scale bar, 25μm. E, Representative images of immunofluorescence staining of NOX5 
in the heart of normal control donors and patients with heart failure, (n = 6). Scale bar, 
20μm. Data were shown in mean±SEM; *P < 0.05, **P < 0.01, n.s., not significant. 
Figure 2. NOX5 promotes cardiomyocyte hypertrophy in vitro. 
A, Immunoblots of NOX5 protein expression in NRVMs infected with AdVector or 
AdNOX5. B, Left, representative immunofluorescence images of α-actinin staining in 
NRVMs infected with AdVector or AdNOX5 and treated for 48 hours with PBS or Ang 
II. Scale bar, 60μm. Right, relative cell surface area of cultured NRVMs infected with 
the indicated adenoviruses in response to PBS or Ang II treatment, (n ≥50 cells per 
group). C, Real-time quantitative PCR (qPCR) analyses of the mRNA levels of 
hypertrophic marker genes (Nppa, Nppb and Myh7) in PBS- or Ang II–treated NRVMs 
infected with AdVector or AdNOX5. (n=4 samples per group). D, Representative 
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immunoblots of Anp and β-MHC protein expression in NRVMs infected with AdVector 
or AdNOX5 treated for 48 hours with PBS or Ang II. E, Left, representative 
immunofluorescence images of α-actinin staining in AC16 cells infected with AdVector 
or AdNOX5 and treated for 48 hours with PBS or Ang II. Scale bar, 60μm. Right, 
relative cell surface area of AC16 cells infected with the indicated adenoviruses in 
response to PBS or Ang II treatment, (n ≥50 cells per group. F, qPCR analyses of the 
mRNA levels of hypertrophic marker genes (Nppa and Myh7) in PBS- or Ang II–treated 
AC16 cells infected with AdVector or AdNOX5, (n=4 samples per group). G, 
Representative immunoblots of Anp and β-MHC protein expression in AC16 cells 
infected with AdVector or AdNOX5 treated for 48 hours with PBS or Ang II. Data were 
shown in mean±SEM; *P < 0.05, **P < 0.01. 
Fig3. NOX5 aggravates pressure overload-induced cardiac hypertrophy. 
A, Schematic diagram depicting the construction of cardiac-specific NOX5- 
overexpressing experimental mice. B, Agarose gel photograph illustrating genotyping 
results of PCR products from WT or NOX5-Tg mice. Sizes are indicated in bp. C, 
Representative immunoblots showing NOX5 expression in heart tissues of WT and 
NOX5-Tg mice. D, The representative B mode and M mode echocardiographic images 
of left ventricle of WT and NOX5-Tg mice at 4 weeks after sham or TAC surgery, (n=9-
12 mice per group). E, Comparison of the echocardiographic parameters left ventricular 
(LV) end-diastolic dimension (LVEDd), LV end-systolic dimension (LVESd), LV 
ejection fraction (LVEF), and LV fraction shortening (LVFS) between the indicated 
groups (n=8 mice per group). F, Ratios of heart weight (HW)/body weight (BW) and 
heart weight to tibia length (HW/TL) in the indicated groups, (n=8 mice per group). G, 
Histological examinations of hematoxylin and eosin-stained (first and second) and 
picrosirius red-stained (third) left ventricle cross-sections from the indicated groups, 
(n=6 mice per group). Scale bar, 1mm for the upper most set of panels and scale bar, 
25μm for lower panels. H, Statistical results of individual cardiomyocyte cross-
sectional area and LV collagen volume in the indicated groups. I, Representative 
Western blots showing the protein levels of Anp, β-MHC, Col1a1, and Col3a1 at 4 
weeks after sham or TAC surgery in WT and NOX5-Tg mice. J, Real-time PCR 
analyses of hypertrophic markers (Nppa, Myh7) and the fibrotic markers (collagen I, 
collagen III) in the indicated mice, (n=4 mice per group). Data were shown in mean±
SEM; *P < 0.05, **P < 0.01, n.s., not significant. 




A, Left, representative immunofluorescence images of dihydroethidium staining in the 
hearts of WT and NOX5-Tg mice at 4 weeks after sham or TAC surgery. Scale bar, 
50μm. Right, quantification of reactive oxygen species levels in the indicated groups 
based on measurement of the intensity of fluorescence, (n＞40 fields per group). B, 
NADPH oxidase activity and O2
- generation in cardiac tissues from WT and NOX5-Tg 
mice assessed by lucigenin chemiluminescence, (n=6 mice per group). Relative 
luminescence units (RLU) were corrected by protein concentration of each sample. C, 
Relative H2O2 levels in cardiac tissues from WT and NOX5-Tg mice assessed by Elisa, 
(n=6 mice per group). D, Left, dihydroethidium staining of reactive oxygen species 
levels in NRVMs infected with AdVector or AdNOX5 and treated for 48 hours with 
PBS or Ang II. Scale bar, 50μm. Right, quantification of reactive oxygen species levels 
of cultured NRVMs infected with the indicated adenoviruses in response to PBS or Ang 
II treatment, (n＞19 fields per group). E, NADPH oxidase activity and O2- generation 
in NRVMs infected with AdVector or AdNOX5 and treated for 48 hours with PBS or 
Ang II, (n=4 samples per group). Relative luminescence units (RLU) were corrected by 
protein concentration of each sample. F, Relative H2O2 levels in NRVMs assessed by 
Elisa, (n=4 samples per group). G, Representative western blotting showing the 
expression of p-Erk, Erk, p-Jnk, Jnk, p-p38, and p38 in heart samples from WT and 
NOX5-Tg mice at 4 weeks after sham or TAC surgery. H, Representative western 
blotting showing the expression of the indicated kinases in NRVMs infected with 
AdVector or AdNOX5 following PBS or Ang II treatment. Data were shown in mean±
SEM; *P < 0.05, **P < 0.01. 
Fig5. Inhibition of ROS abolishes the NOX5-mediated pro-hypertrophic effect in 
vivo. 
A, Comparison of the echocardiographic parameters left ventricular (LV) end-diastolic 
dimension (LVEDd), LV end-systolic dimension (LVESd), LV ejection fraction (LVEF), 
and LV fraction shortening (LVFS) between the WT and NOX5-Tg mice treated with 
saline or NAC after TAC surgery for 4 weeks, (n=11-12 mice per group). B, The ratio 
of HW/BW and HW/TL in the indicated groups, (n=8 mice per group). C-D, Left, 
representative images of H&E staining and PSR staining of hearts from the indicated 
groups, (n=6 mice per group). Scale bar, 1mm for the upper panel and scale bar, 25μm 
for the lower panel. Right, statistical results of the cardiomyocyte cross-sectional area 
and LV collagen volume in the indicated groups. E, NADPH oxidase activity and O2- 
generation in NRVMs infected with AdVector, AdNOX5 or AdNOX5(M) and treated 
for 48 hours with Ang II. Relative luminescence units (RLU) were corrected by protein 
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concentration of each sample, (n=4 samples per group). F, Left, representative 
immunofluorescence images of α-actinin staining in NRVMs infected with AdVector, 
AdNOX5 or AdNOX5(M) and treated with Ang II for 48 hours, scale bar, 60μm; Right, 
Relative cell surface area. (n ≥50 cells per group). G, Real-time quantitative PCR 
(qPCR) analyses of the mRNA levels of hypertrophic marker genes (Nppa and Myh7) 
in the indicated groups, (n=4 samples per group). H, Representative immunoblots of 
Anp, β-MHC and NOX5 proteins expression in the indicated groups. Data were shown 
in mean±SEM; *P < 0.05, **P < 0.01. 
Fig6. Activity of NOX5 is Ca2+ dependent.  
A, Relative intracellular Ca2+ concentration detected by Fluo 4-AM in the indicated 
groups. B, NADPH oxidase activity assessed by enhanced lucigenin assay in the 
indicated group. Relative luminescence units (RLU) were corrected by protein 
concentration of each sample, (n=4 samples per group). C, Left, Representative 
immunofluorescence images of α-actinin staining in NRVMs infected with AdVector 
or AdNOX5 and treated for 48 hours with PBS or Ang II in the presence or absence of 
diltiazem, scale bar, 60μm; Right, Quantitative analysis of the cell surface area, (n≥50 
cells per group). D, mRNA levels of the hypertrophic marker genes (Nppa and Myh7) 
in the indicated groups. E, Schematic figure. Data were shown in mean±SEM; *P < 
0.05, **P < 0.01, n.s., not significant. 
